Embody vs Revel Health
Two headline figures that expire in different ways.
Embody
Editorial
$79/mo
Embody shows $79 a month for compounded semaglutide and $129 for compounded tirzepatide, both struck through from higher anchors, and both reached by a promotion applied automatically at checkout. Its terms list $199 a month. The oral preparations are priced separately at $229 and $329.
Pick it for: Readers comparing the standing rate rather than the promotion
Revel Health
Editorial
$149/mo
Revel Health advertises compounded semaglutide at $199 a month by injection and $149 as an oral dissolving tablet, with compounded tirzepatide at $249 and $199 on the same pattern. The oral is the cheaper route on both molecules, which reverses the usual order. Each line also carries a reduced first month, and the seller states that consultation, medication, supplies and shipping are included in the rate. Forty-five states.
Pick it for: Readers who want consultation and shipping inside the ongoing figure
Our verdict
Embody advertises a promotional rate against a higher listed one. Revel Health advertises a first month against a higher ongoing rate. Neither headline is what month two costs.
What actually separates them
Embody and Revel Health state different things about published price. Everything else they publish, they publish the same way.
Revel Health costs $70 more than Embody — 89% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $948 at Embody against $1,788 at Revel Health — a difference of $840.
| Embody | Revel Health | |
|---|---|---|
| Published price | $79/mo | $149/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.